Background: Maraviroc, an antagonist of the human chemokine receptor CCR5, is being developed for the treatment of HIV-1 infection. Previous findings showed a disproportional increase in AUC with increasing doses and food effects on both bioavailability (F) and absorption rate constant (ka). The aim of this analysis was to describe the population pharmacokinetics (PK) of maraviroc […]
